Shared on01 Aug 25Fair value Decreased 9.00%
Recursion Pharmaceuticals’ consensus price target has been revised downward to $6.67 as analysts cite sector volatility, disappointing early clinical results, unresolved questions around pipeline valuation and revenue drivers, and the company’s early-stage status as key concerns. Analyst Commentary Volatility driven by macroeconomic factors impacting the biotech sector.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 3.21%
AnalystConsensusTarget has increased revenue growth from 45.2% to 64.7%, decreased profit margin from 19.3% to 17.3% and decreased future PE multiple from 153.4x to 113.7x.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 26%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.